Cardiac events occurring after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Study conducted on behalf of the GETH-TC-Reference-Cited by-同舟云学术

Cardiac events occurring after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Study conducted on behalf of the GETH-TC

Published:2024-09-14 Issue: Volume: Page:
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Salas María Queralt^ORCID,Cascos Enric,López-García Alberto,Pérez-López Estefanía,Baile-González Mónica,López-Corral Lucía^ORCID,Pascual Cascón María Jesús,Luque Marta,Esquirol Albert^ORCID,Heras Fernando Inmaculada,Oiartzabal Ormtegi Itziar,Sáez Marín Adolfo Jesús^ORCID,Peña-Muñóz Felipe,Fernández-Luis Sara^ORCID,Domínguez-García Juan José^ORCID,Villar Fernández Sara^ORCID,Fernández de Sanmamed Girón Miguel,González Pinedo Leslie,González-Rodríguez Ana Pilar,Torrado Tamara,García Lucía,Filaferro Silvia,Cedillo Ángel,Basalobre Pascual,Ortí Guillermo,Jurado Chacón Manuel

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41409-024-02414-z.pdf

Reference34 articles.

1. Lyon AR, Lopez-Fernandez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging. 2022;23:e333–e465.

2. Braverman AC, Antin JH, Plappert MT, Cook EF, Lee RT. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol. 1991;9:1215–23.

3. Ishida S, Doki N, Shingai N, Yoshioka K, Kakihana K, Sakamaki H, et al. The clinical features of fatal cyclophosphamide-induced cardiotoxicity in a conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Ann Hematol. 2016;95:1145–50.

4. Marumo A, Omori I, Tara S, Otsuka Y, Konuma R, Adachi H, et al. Cyclophosphamide-induced cardiotoxicity at conditioning for allogeneic hematopoietic stem cell transplantation would occur among the patients treated with 120 mg/kg or less. Asia Pac J Clin Oncol. 2022;18:e507–e14.

5. Rotz S, Hamilton BK. Post-transplantation cyclophosphamide: an old nemesis to a new transplant paradigm?. JACC CardioOncol. 2021;3:260–2.